Welcome to our dedicated page for MaxCyte news (Ticker: MXCT), a resource for investors and traders seeking the latest updates and insights on MaxCyte stock.
MaxCyte, Inc. reports news on its cell-engineering technology business for biotechnology and pharmaceutical customers developing next-generation cell therapeutics. Company updates center on Flow Electroporation technology, ExPERT instruments, SeQure gene editing assessment services, and Strategic Platform License relationships that can generate product, license, research, clinical and program-related revenue.
Recurring developments include quarterly and annual financial results, revenue guidance, installed instrument activity, licensed customer programs, product launches such as ExPERT DTx for high-throughput electroporation, and corporate governance matters including executive appointments and equity compensation grants.
MaxCyte, a leader in cell-engineering technologies, will release its second-quarter financial results on September 13, 2021, after the U.S. market closes. The company will host a conference call at 4:30 p.m. ET to discuss the results. MaxCyte serves numerous biopharmaceutical companies, including 20 of the top 25 by global revenue, and has granted 14 strategic platform licenses for over 75 clinical programs. The conference call will be accessible via a dedicated phone line and webcast.
MaxCyte has signed a clinical and commercial license agreement with Sana Biotechnology, granting Sana the rights to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform. In return, MaxCyte will receive licensing fees and milestone payments. Doug Doerfler, MaxCyte's CEO, expressed enthusiasm for supporting Sana's cell therapy programs, highlighting the potential of Sana's hypoimmune cell platform. This collaboration aims to enhance the development of innovative cell-based treatments, reinforcing MaxCyte's position in the biopharmaceutical sector.
DLA Piper acted as legal counsel for underwriters Cowen, Stifel, and William Blair in MaxCyte's IPO of 13,500,000 shares at $13.00 each, potentially raising $175.5 million. The underwriters have a 30-day option to purchase an additional 2,025,000 shares. Closing is anticipated around August 3, 2021, pending customary conditions. DLA Piper's expertise in capital markets and life sciences played a significant role in this transaction.
MaxCyte, Inc. (LSE: MXCT) announced the pricing of an upsized offering of 13,500,000 shares at US$13.00 each, projected to raise gross proceeds of approximately US$175.5 million. The net proceeds will support R&D, manufacturing expansions, and general corporate purposes. Trading on the Nasdaq is set to begin on July 30, 2021. Additionally, related party Casdin Partners aims to purchase 1,800,000 shares, which will give them a 14% stake post-offering. The closing of the offering is expected on August 3, 2021.